<?xml version="1.0" encoding="UTF-8"?>
<ref id="B208">
 <label>208.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rilinger</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Kern</surname>
    <given-names>WV</given-names>
   </name>
   <name>
    <surname>Duerschmied</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Supady</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Bode</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Staudacher</surname>
    <given-names>DL</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial</article-title>. 
  <source>Trials.</source> (
  <year>2020</year>) 
  <volume>21</volume>:
  <fpage>470</fpage>. 
  <pub-id pub-id-type="doi">10.1186/s13063-020-04447-3</pub-id>
  <?supplied-pmid 32493514?>
  <pub-id pub-id-type="pmid">32493514</pub-id>
 </mixed-citation>
</ref>
